ENMD-2076
2076-CL-005
Phase 2 small_molecule completed
Quick answer
ENMD-2076 for Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CASI Pharmaceuticals
- Indication
- Triple Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed